ClinicalTrials.gg
CompletedNCT04197479MAESTRO-NAFLD1Updated Sep 5, 2023

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

A Phase 3 interventional study of Placebo and Resmetirom in Non-Alcoholic Fatty Liver Disease, sponsored by Madrigal Pharmaceuticals, Inc.. Completed at 77 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,343
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
12th of 460
1,343 · median 56
Started
2019
with 61 others
Phase 3
29 of 547
7 open now
Registered
325th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 12th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 29 in phase 3, and was the 325th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. At least 100 patients will be enrolled in a 100 mg open-label arm and will include a special safety population (eg, patients with compensated NASH cirrhosis).

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease

Keywords

  • NAFLD
  • NASH
  • Hyperlipidemia
  • Resmetirom
  • Thyroid hormone receptor beta
  • Hepatic
  • Fibrosis
  • NASH resolution
  • Thyroid hormone receptor agonist
  • Cardiovascular
  • Dyslipidemia
  • Fatty liver disease
  • Nonalcoholic steatohepatitis
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to participate in the study and provide written .
  • Male and female adults ≥18 years of age.
  • Suspected or confirmed diagnosis of NASH or NAFLD (presumed NASH):

    • Fibroscan with kPa ≥5.5 and \<8.5; CAP ≥280 dB.m-1 OR
    • MRE ≥2 and \<4.0; MRI-PDFF ≥8% liver fat consistent with steatosis and fibrosis stage ≥1 and \<4. OR
    • Recent liver (within past 2 years) documenting NASH/NAFLD with steatosis showing one of the following:

      • NAS ≥4, steatosis ≥1, fibrosis stage 0 or F1A/1C with PRO-C3 \<14
      • NAS \<4, steatosis ≥1, with fibrosis stage ≤3
      • NAS ≥4, steatosis ≥1, fibrosis stage ≤3 without ballooning

        • NOTE: Since the completion of enrollment of the double-blind arms, patients meeting all other criteria who have a liver biopsy result from MGL-3196-11 with the following may be enrolled in the open-label active treatment arm of MGL-3196-14 (100 mg dose):

          • NAS = 3, steatosis 1, ballooning 1, inflammation 1 with F2 or F3
          • NAS = 3, ballooning 0 with F2 or F3
        • For the compensated NASH cirrhosis arm, eligible patients must have compensated NASH cirrhosis diagnosed by liver biopsy showing NASH with F4 stage fibrosis (either historic or recent biopsy) or a historic biopsy with NASH F2-F3 fibrosis with subsequent progression to NASH cirrhosis as diagnosed by an expert hepatologist/gastroenterologist.
    • Compensated NASH cirrhosis at screening and baseline includes

      • -A (score 5-6) ( may have either mild hepatic encephalopathy OR mild diuretic responsive ascites OR albumin \< 3.5 and ≥ 3.2 (not any two of these, unless explained by Gilbert's Syndrome or non-hepatic causes)).
      • MELD \< 12 at screening/baseline unless MELD ≥ 12 based on non-cirrhotic parameters (e.g., elevated due to anticoagulation, elevation due to documented Gilbert's Syndrome, elevated creatine due to renal disease (non-hepatic)).
      • Albumin ≥ 3.2.
      • Bilirubin \< 2 (unless documented Gilbert's Syndrome).
  • MRI-PDFF fat fraction ≥8% obtained during the Screening Period (baseline MRI-PDFF) or a historic MRI-PDFF ≤8 weeks old at the time of randomization.
  • Stable dyslipidemia therapy for ≥30 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening.
  • Regular use of drugs historically associated with NAFLD.
  • History of bariatric surgery or intestinal bypass surgery within the 5 years prior to randomization or planned during the conduct of the study.
  • Weight gain or loss ≥5% total body weight within 12 weeks prior to randomization.
  • >9.0%.
  • Glucagon-like peptide 1 [GLP-1] agonist therapy or high dose vitamin E (>400 IU/day) unless stable for 24 weeks prior to .
  • Presence of cirrhosis on liver biopsy defined as stage 4 fibrosis.
  • Diagnosis of hepatocellular carcinoma (HCC).
  • Model for End-stage Liver Disease (MELD) score ≥12, as determined at Screening, unless due to therapeutic anti coagulation or Gilbert syndrome.
  • Hepatic decompensation.
  • Chronic liver diseases.
  • Has an active disease.
  • Serum >250 U/L.
  • History of biliary diversion.
  • Uncontrolled hypertension (either treated or untreated).
  • Active, serious medical disease with a likely \<2 years.
  • Participation in an new drug trial in the 60 days or 5 half-lives, whichever is longer, prior to randomization.
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,343 participants (actual)

Study arms

  • Experimental
    Open label: resmetirom

    100 mg daily

    Drug: Resmetirom

  • Placebo comparator
    Double blinded: matching placebo

    Placebo daily

    Drug: Placebo

  • Experimental
    Double blinded: resmetirom 80 mg

    80 mg daily

    Drug: Resmetirom

  • Experimental
    Double blinded: resmetirom 100 mg

    100 mg daily

    Drug: Resmetirom

Interventions

  • DrugPlacebo

    Matching tablets

  • Tablet

    Also known as: MGL-3196

06

What researchers measure

Primary outcomes

  1. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events.

    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events.

    Time frame: 52 weeks

Secondary outcomes

  1. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in low density lipoprotein C (LDL-C) from baseline to Week 24

    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in low density lipoprotein C (LDL-C) from baseline to Week 24

    Time frame: 24 weeks

  2. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in apolipoprotein B (ApoB) from baseline to Week 24

    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in apolipoprotein B (ApoB) from baseline to Week 24

    Time frame: 24 weeks

  3. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in hepatic fat fraction as determined by MRI-PDFF from baseline to Week 16.

    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in hepatic fat fraction as determined by MRI-PDFF from baseline to Week 16.

    Time frame: 16 weeks

  4. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in triglycerides (TGs) from baseline to Week 24 in patients with baseline TG > 150 mg/dL.

    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in triglycerides (TGs) from baseline to Week 24 in patients with baseline TG \> 150 mg/dL.

    Time frame: 24 weeks

  5. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo after 52 weeks on FibroScan controlled attenuation parameter (CAP)

    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo after 52 weeks on FibroScan controlled attenuation parameter (CAP)

    Time frame: 52 weeks

  6. The change from baseline to Week 52 in FibroScan vibration controlled transient elastography (kPa)

    The change from baseline to Week 52 in FibroScan vibration controlled transient elastography (VCTE) (kPa) in patients with baseline kPa \>/=7.2 and a Week 52 or end of treatment FibroScan (VCTE)

    Time frame: 52 weeks

07

Study locations

77 sites
  • Central Research Associates
    Birmingham, Alabama 35205, United States
  • Arizona Liver Health - Chandler
    Chandler, Arizona 85224, United States
  • East Valley Family Physicians
    Chandler, Arizona 85224, United States
  • The Institute For Liver Health - Glendale
    Glendale, Arizona 85306, United States
  • Arizona - Desert Clinical Research
    Mesa, Arizona 85213, United States
  • The Institute For Liver Health - Tucson
    Tucson, Arizona 85711, United States
  • Adobe Gastroenterology
    Tucson, Arizona 85712, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Fresno Clinical Research Center
    Fresno, California 93720, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • Ruane Clinical Research Group
    Los Angeles, California 90036, United States
  • National Research Institute - Los Angeles
    Los Angeles, California 90057, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • National Research Institute - Panorama City
    Panorama City, California 91402, United States
  • Alliance Clinical Research
    Poway, California 92064, United States
  • San Fernando Valley Health Institute
    West Hills, California 91307, United States
  • South Denver Gastroenterology - Swedish Medical Center Office
    Englewood, Colorado 80113, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Velocity Clinical Research, Hallandale Beach (MD Clinical)
    Hallandale Beach, Florida 33009, United States
  • Floridian Clinical Research
    Hialeah, Florida 33016, United States
  • Nature Coast Clinical Research - Inverness
    Inverness, Florida 34452, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • Miami Dade Medical Research Institute
    Miami, Florida 33176, United States
  • Orlando Research Center
    Orlando, Florida 32806, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Covenant Research
    Sarasota, Florida 34240, United States
  • The Villages Research Center
    The Villages, Florida 32162, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Chicago Research Center
    Chicago, Illinois 60602, United States
  • Northwestern Memorial Physicians Group
    Chicago, Illinois 60611, United States
  • Iowa Diabetes Research
    West Des Moines, Iowa 50265, United States
  • Kansas Medical Clinic - Gastroenterology
    Topeka, Kansas 66606, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Digestive Health Center of Louisiana
    Baton Rouge, Louisiana 70809, United States
  • Tandem Clinical Research - New Orleans Area Site
    Marrero, Louisiana 70072, United States
  • Clinical Trials of America
    West Monroe, Louisiana 71291, United States
  • Huron Gastroenterology
    Ypsilanti, Michigan 48197, United States
  • Gastrointestinal Associates & Endoscopy Center - Flowood
    Flowood, Mississippi 39232, United States
  • Southern Therapy and Advanced Research
    Jackson, Mississippi 39216, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Henderson Research Center
    Henderson, Nevada 89052, United States
  • Clarity Clinical Research
    East Syracuse, New York 13057, United States
  • Mount Sinai Health System
    New York, New York 10029, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cumberland Research Associates
    Fayetteville, North Carolina 28304, United States
  • Diabetes and Endocrinology Consultants
    Morehead City, North Carolina 28557, United States
  • TMA - Wilmington Gastroenterology Accociates
    Wilmington, North Carolina 28403, United States
  • Platinum - Sterling Research Group - Springdale
    Cincinnati, Ohio 45246, United States
  • Aventiv Research Columbus
    Columbus, Ohio 43213, United States
  • Awasty Research Network
    Marion, Ohio 43302, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • Premier Medical Group - Clarksville - Dunlop Lane
    Clarksville, Tennessee 37040, United States
  • Gastro One - Germantown Office - Wolf Park Drive
    Germantown, Tennessee 38138, United States
  • Pinnacle Clinical Research - Austin
    Austin, Texas 78746, United States
  • The Liver Institute At Methodist Dallas
    Dallas, Texas 75203, United States
  • Dallas Research Center
    Dallas, Texas 75234, United States
  • Liver Center of Texas
    Dallas, Texas 75234, United States
  • Texas Digestive Disease Consultants - Dallas - Baylor University Medical Center Gaston Ave
    Dallas, Texas 75246, United States
  • South Texas Research Institute
    Edinburg, Texas 78539, United States
  • Texas Digestive Disease Consultants - Forth Worth - Downtown
    Fort Worth, Texas 76104, United States
  • Liver Associates of Texas
    Houston, Texas 77030, United States
  • Doctor's Hospital at Renaissance
    McAllen, Texas 78504, United States
  • Plano Research Center
    Plano, Texas 75093, United States
  • Texas Liver Institute/American Research Corporation
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research - San Antonio
    San Antonio, Texas 78229, United States
  • San Antonio Research Center
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants - San Marcos
    San Marcos, Texas 78666, United States
  • Texas Digestive Disease Consultants - Bay Area Houston Endoscopy Center
    Webster, Texas 77598, United States
  • Wasatch Peak Family Practice
    Layton, Utah 84041, United States
  • Salt Lake City Research Center
    Murray, Utah 84123, United States
  • Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • National Clinical Research - Richmond
    Richmond, Virginia 23294, United States
  • Virginia Commonwealth University School of Medicine
    Richmond, Virginia 23298, United States
  • Liver Institute Northwest
    Seattle, Washington 98105, United States
  • Fundacion de Investigacion de Diego
    San Juan, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jan 2023, 36 months.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2019
First posted
Dec 13, 2019
StartActual
Dec 16, 2019
Primary completionActual
Jan 6, 2023
CompletionActual
Jan 6, 2023
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04197479
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Dec 16, 2019
Primary completion
Jan 6, 2023
Completion
Jan 6, 2023
Last update
Sep 5, 2023

Study contacts

Rebecca Taub, MD
study director · Madrigal Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resmetirom

Start the discussion